I received a response back from Fred Sommer in IR today.
I received a response back from Fred Sommer in IR today. My email to him:
Hi Fred,
There was no shareholder meeting on or before June 6th as agreed upon in the latest filings with the major note holders.
There was a pr issued on March 22nd when the previous shareholders meeting scheduled for March 29th was cancelled, but there was no pr issued this time. Why not?
There is no reason that Management couldn't issue a pr stating that this latest meeting was cancelled, postponed, etc.
When can we expect an update as to the status of the proposed RS. increased A/S increase and annual shareholder meeting? "
His response back to me:
"I expect to have some answers in the next couple of weeks. With that said, the RS is not something that is being entertained at this time. Call in whenever you want to chat. Thanks for your support"
So just as I suspected, the RS is off the table - at least for now.
14
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Introducing the 7406 Incubator Shaker by Caron Scientific Caron Scientific, Inc. has raised the bar in environmental testing and laboratory equipment with the launch of their newest innovation: the 7406 Incubator Shaker. Known for its dedication to providing state-of-the-art incubation solutions, Caron Scientific presented this remarkable product at a prominent...
Continue Reading
US Stocks Look to Rebound Following Recent Sell-Off U.S. stock futures showed an upward trend recently, bouncing back from a notable sell-off. Most benchmark indices are witnessing gains in premarket trading while the small-cap Russell 2000 remains slightly down. Nvidia's Effects on Technology Sector Nvidia Corp. (NASDAQ: NVDA) experienced a significant decline of over 8%...
Continue Reading
Understanding the Avantor, Inc. Class Action Lawsuit Avantor, Inc. (NYSE: AVTR) is a prominent provider of scientific products and services designed to cater to various sectors including biotechnology and pharmaceuticals. This article sheds light on the ongoing class action lawsuit initiated on behalf of investors who acquired shares of Avantor during a specified class...
Continue Reading
Hyphens Pharma Collaborates with Louis Widmer for Cerapro® MED Hyphens Pharma International Limited is thrilled to announce a significant partnership with Louis Widmer SA for the commercialization of their innovative product, Cerapro® MED Skin Barrier Cream. This agreement enables Louis Widmer to promote and distribute Cerapro® MED in six European countries. About...
Continue Reading
Engagement in a Notable Investor Conference Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has exciting news for its stakeholders! The company recently declared its participation in an essential fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference. This event is set to take place in Boston and will commence at 11:30 a.m. PT / 2:30 p.m. ET on a Tuesday...
Continue Reading